Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy

Maki Hagihara, Heiwa Kanamori, Miwa Sakai, Takehiko Mori, Chiaki Nakaseko, Nobuyuki Aotsuka, Taeko Uehara, Tohru Sakura, Fumio Yoshiba, Nobutaka Kawai, Masatsugu Tanaka, Shin Fujisawa, Chikako Ohwada, Hisashi Wakita, Akira Yokota, Toshihide Kawamura, Atsuo Maruta, Hisashi Sakamaki, Shinichiro Okamoto, Study Group for Cell Therapy (KSGCT) Kanto Study Group for Cell Therapy (KSGCT)

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We retrospectively surveyed patients who received a second transplantation for graft failure (GF) after allogeneic hematopoietic stem cell transplantation (SCT) in hospitals participating in the Kanto Study Group for Cell Therapy. A second SCT was performed in 21 of 45 patients with primary GF and in 13 of 15 with secondary GF. The median time between the first and second SCT was 49 days (range, 18-1204 days). The diagnosis included 28 patients with hematologic malignancies and 6 with aplastic anemia. Non-myeloablative or reduced-intensity conditioning was performed in 30 patients. Cord blood was frequently used as the source of stem cells followed by related donor peripheral blood, and unrelated bone marrow. Engraftment was achieved in 23 patients (68%). Conditioning regimen including total body or total lymphoid irradiation, was significantly associated with a higher engraftment rate. Overall survival at 5 years in all patients who underwent second SCT was 34%. Prognostic factors for better survival after second SCT were a time to second SCT longer than 90 days, the performance status at second SCT with 0 or 1, and the administration of tacrolimus for GVHD prophylaxis. The major cause of death after second SCT was infection. Although the outcome of a second SCT for graft failure remains poor, these findings suggest that the selection of patients as well as transplant methods, such as conditioning and GVHD prophylaxis, may contribute to survival.

Original languageEnglish
Pages (from-to)390-397
Number of pages8
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume51
Issue number6
Publication statusPublished - 2010 Jun
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Group Psychotherapy
Cell- and Tissue-Based Therapy
Transplantation
Transplants
Survival
Lymphatic Irradiation
Unrelated Donors
Surveys and Questionnaires
Aplastic Anemia
Tacrolimus
Hematologic Neoplasms
Blood Donors
Fetal Blood
Patient Selection
Cause of Death
Stem Cells
Bone Marrow
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hagihara, M., Kanamori, H., Sakai, M., Mori, T., Nakaseko, C., Aotsuka, N., ... Kanto Study Group for Cell Therapy (KSGCT), S. G. F. C. T. KSGCT. (2010). Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy. [Rinshō ketsueki] The Japanese journal of clinical hematology, 51(6), 390-397.

Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy. / Hagihara, Maki; Kanamori, Heiwa; Sakai, Miwa; Mori, Takehiko; Nakaseko, Chiaki; Aotsuka, Nobuyuki; Uehara, Taeko; Sakura, Tohru; Yoshiba, Fumio; Kawai, Nobutaka; Tanaka, Masatsugu; Fujisawa, Shin; Ohwada, Chikako; Wakita, Hisashi; Yokota, Akira; Kawamura, Toshihide; Maruta, Atsuo; Sakamaki, Hisashi; Okamoto, Shinichiro; Kanto Study Group for Cell Therapy (KSGCT), Study Group for Cell Therapy (KSGCT).

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 51, No. 6, 06.2010, p. 390-397.

Research output: Contribution to journalArticle

Hagihara, M, Kanamori, H, Sakai, M, Mori, T, Nakaseko, C, Aotsuka, N, Uehara, T, Sakura, T, Yoshiba, F, Kawai, N, Tanaka, M, Fujisawa, S, Ohwada, C, Wakita, H, Yokota, A, Kawamura, T, Maruta, A, Sakamaki, H, Okamoto, S & Kanto Study Group for Cell Therapy (KSGCT), SGFCTKSGCT 2010, 'Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy', [Rinshō ketsueki] The Japanese journal of clinical hematology, vol. 51, no. 6, pp. 390-397.
Hagihara, Maki ; Kanamori, Heiwa ; Sakai, Miwa ; Mori, Takehiko ; Nakaseko, Chiaki ; Aotsuka, Nobuyuki ; Uehara, Taeko ; Sakura, Tohru ; Yoshiba, Fumio ; Kawai, Nobutaka ; Tanaka, Masatsugu ; Fujisawa, Shin ; Ohwada, Chikako ; Wakita, Hisashi ; Yokota, Akira ; Kawamura, Toshihide ; Maruta, Atsuo ; Sakamaki, Hisashi ; Okamoto, Shinichiro ; Kanto Study Group for Cell Therapy (KSGCT), Study Group for Cell Therapy (KSGCT). / Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy. In: [Rinshō ketsueki] The Japanese journal of clinical hematology. 2010 ; Vol. 51, No. 6. pp. 390-397.
@article{7bd02c387f894a8e9d19e345a709bd86,
title = "Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy",
abstract = "We retrospectively surveyed patients who received a second transplantation for graft failure (GF) after allogeneic hematopoietic stem cell transplantation (SCT) in hospitals participating in the Kanto Study Group for Cell Therapy. A second SCT was performed in 21 of 45 patients with primary GF and in 13 of 15 with secondary GF. The median time between the first and second SCT was 49 days (range, 18-1204 days). The diagnosis included 28 patients with hematologic malignancies and 6 with aplastic anemia. Non-myeloablative or reduced-intensity conditioning was performed in 30 patients. Cord blood was frequently used as the source of stem cells followed by related donor peripheral blood, and unrelated bone marrow. Engraftment was achieved in 23 patients (68{\%}). Conditioning regimen including total body or total lymphoid irradiation, was significantly associated with a higher engraftment rate. Overall survival at 5 years in all patients who underwent second SCT was 34{\%}. Prognostic factors for better survival after second SCT were a time to second SCT longer than 90 days, the performance status at second SCT with 0 or 1, and the administration of tacrolimus for GVHD prophylaxis. The major cause of death after second SCT was infection. Although the outcome of a second SCT for graft failure remains poor, these findings suggest that the selection of patients as well as transplant methods, such as conditioning and GVHD prophylaxis, may contribute to survival.",
author = "Maki Hagihara and Heiwa Kanamori and Miwa Sakai and Takehiko Mori and Chiaki Nakaseko and Nobuyuki Aotsuka and Taeko Uehara and Tohru Sakura and Fumio Yoshiba and Nobutaka Kawai and Masatsugu Tanaka and Shin Fujisawa and Chikako Ohwada and Hisashi Wakita and Akira Yokota and Toshihide Kawamura and Atsuo Maruta and Hisashi Sakamaki and Shinichiro Okamoto and {Kanto Study Group for Cell Therapy (KSGCT)}, {Study Group for Cell Therapy (KSGCT)}",
year = "2010",
month = "6",
language = "English",
volume = "51",
pages = "390--397",
journal = "[Rinshō ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "6",

}

TY - JOUR

T1 - Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy

AU - Hagihara, Maki

AU - Kanamori, Heiwa

AU - Sakai, Miwa

AU - Mori, Takehiko

AU - Nakaseko, Chiaki

AU - Aotsuka, Nobuyuki

AU - Uehara, Taeko

AU - Sakura, Tohru

AU - Yoshiba, Fumio

AU - Kawai, Nobutaka

AU - Tanaka, Masatsugu

AU - Fujisawa, Shin

AU - Ohwada, Chikako

AU - Wakita, Hisashi

AU - Yokota, Akira

AU - Kawamura, Toshihide

AU - Maruta, Atsuo

AU - Sakamaki, Hisashi

AU - Okamoto, Shinichiro

AU - Kanto Study Group for Cell Therapy (KSGCT), Study Group for Cell Therapy (KSGCT)

PY - 2010/6

Y1 - 2010/6

N2 - We retrospectively surveyed patients who received a second transplantation for graft failure (GF) after allogeneic hematopoietic stem cell transplantation (SCT) in hospitals participating in the Kanto Study Group for Cell Therapy. A second SCT was performed in 21 of 45 patients with primary GF and in 13 of 15 with secondary GF. The median time between the first and second SCT was 49 days (range, 18-1204 days). The diagnosis included 28 patients with hematologic malignancies and 6 with aplastic anemia. Non-myeloablative or reduced-intensity conditioning was performed in 30 patients. Cord blood was frequently used as the source of stem cells followed by related donor peripheral blood, and unrelated bone marrow. Engraftment was achieved in 23 patients (68%). Conditioning regimen including total body or total lymphoid irradiation, was significantly associated with a higher engraftment rate. Overall survival at 5 years in all patients who underwent second SCT was 34%. Prognostic factors for better survival after second SCT were a time to second SCT longer than 90 days, the performance status at second SCT with 0 or 1, and the administration of tacrolimus for GVHD prophylaxis. The major cause of death after second SCT was infection. Although the outcome of a second SCT for graft failure remains poor, these findings suggest that the selection of patients as well as transplant methods, such as conditioning and GVHD prophylaxis, may contribute to survival.

AB - We retrospectively surveyed patients who received a second transplantation for graft failure (GF) after allogeneic hematopoietic stem cell transplantation (SCT) in hospitals participating in the Kanto Study Group for Cell Therapy. A second SCT was performed in 21 of 45 patients with primary GF and in 13 of 15 with secondary GF. The median time between the first and second SCT was 49 days (range, 18-1204 days). The diagnosis included 28 patients with hematologic malignancies and 6 with aplastic anemia. Non-myeloablative or reduced-intensity conditioning was performed in 30 patients. Cord blood was frequently used as the source of stem cells followed by related donor peripheral blood, and unrelated bone marrow. Engraftment was achieved in 23 patients (68%). Conditioning regimen including total body or total lymphoid irradiation, was significantly associated with a higher engraftment rate. Overall survival at 5 years in all patients who underwent second SCT was 34%. Prognostic factors for better survival after second SCT were a time to second SCT longer than 90 days, the performance status at second SCT with 0 or 1, and the administration of tacrolimus for GVHD prophylaxis. The major cause of death after second SCT was infection. Although the outcome of a second SCT for graft failure remains poor, these findings suggest that the selection of patients as well as transplant methods, such as conditioning and GVHD prophylaxis, may contribute to survival.

UR - http://www.scopus.com/inward/record.url?scp=77957653555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957653555&partnerID=8YFLogxK

M3 - Article

C2 - 20622484

AN - SCOPUS:77957653555

VL - 51

SP - 390

EP - 397

JO - [Rinshō ketsueki] The Japanese journal of clinical hematology

JF - [Rinshō ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 6

ER -